Press Releases

[Jan 2012] PolyTherics acquires Warwick Effect Polymers and expands technology portfolio to enable the development of better biopharmaceuticals

ENHANCED OFFERING INCLUDES LOW VISCOSITY POLYMERS FOR CREATION OF LONGER-ACTING DRUGS AND A NOVEL DRUG TARGETING TECHNOLOGY

London, UK, 20 January 2012 – PolyTherics Limited (“PolyTherics”), a provider of solutions to biopharmaceutical companies for the improvement of protein and peptide based drugs, is pleased to announce the acquisition of Warwick Effect Polymers (“WEP”), a provider of specialty biopolymers for the modification of biological products.